Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC25A1 | P53007 | 1/20 | 0.64 |
| ▸ | SLC10A6 | Q3KNW5 | 3/20 | 0.61 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.61 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.57 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 2/20 | 0.54 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597819 | 0.88 | SLC25A1 (0.60) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL5597716 | 0.85 | ALDH1A1 (0.59) | SLC25A1DNMT1METAP2CCKBRPKM | |
| SCHEMBL30777866 | 0.84 | SLC10A6 (0.75) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL27089455 | 0.84 | SLC10A6 (0.75) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL5598236 | 0.84 | SLC10A6 (0.86) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL5597781 | 0.82 | DDX3X (0.57) | SLC10A6SLC10A2SLC10A1METAP2LMNA | |
| SCHEMBL5597721 | 0.80 | METAP2 (0.80) | SLC10A6SLC10A2SLC10A1METAP2KDM1A | |
| SCHEMBL5598077 | 0.80 | MAPT (0.61) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL10389335 | 0.78 | SLC25A1 (0.75) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 | |
| SCHEMBL810667 | 0.78 | MAPT (0.64) | SLC25A1SLC10A6SLC10A2SLC10A1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | SLC25A1 103/4885SLC10A6 12/4885SLC10A2 81/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | SLC25A1 108/4885SLC10A6 10/4885SLC10A2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.